Lightpoint Medical is a technology leader in targeted cancer surgery. We are developing miniaturized imaging and sensing tools for more precise intra-operative cancer detection. Our mission is to improve the lives of people with cancer by transforming the efficacy of minmally-invasive and robot-assisted procedures.
Over recent decades, robots have transformed cancer surgery. However, in spite of the technological advances in robotic platforms, surgeons still remain completely dependent on their sight to detect cancer intra-operatively. As a result, surgeons often leave cancer behind or remove more healthy tissue than needed. Residual disease increases the need for further drug treatment, radiotherapy, and surgery. Similarly, removing healthy, functional tissue increases post-surgical complications and escalates healthcare costs.
At Lightpoint, we are optimizing the performance of minimally-invasive and robotic cancer surgery, by developing miniaturized imaging and sensing tools to accurately detect cancer intra-operatively. The aims of the tools are to aid surgical decision making, improve patient outcomes and save costs for healthcare system.
Lightpoint has a pipeline of miniaturized tools in development. The technologies incorporate recent advances in miniaturized sensors and detect cancer-targeted drugs already validated for whole-body imaging, such as SPECT/PET scans. The miniaturized probes aim to accurately identify cancer, enabling the full removal of diseased tissue, or confirm its absence, helping to preserve healthy, functional tissue. SENSEI® is our first robotic probe. Find out more in the video below.
SENSEI®, Lightpoint's miniaturized probe designed for intra-operative detection of sentinel lymph nodes as well as cancer metastasis through the lymphatic system, has received regulatory approval in the EU.
SENSEI®, our miniaturized probe for minimally-invasive and robot-assisted cancer surgery, has been successfully registered with the FDA and is now authorized for sale in the US.
Dr Lluis Fumado and the team at Hospital del Mar, Barcelona, is the first to initiate in a multi-center clinical trial with SENSEI® in prostate cancer surgery.
TECNASA, Technologias Asociadas will be responsible for the distribution and sale of SENSEI® in Spain and Portugal.
The Australian Government Department of Health has approved the sale of SENSEI® in Australia.
Surgeon's Choice will be responsible for the distribution and sale of SENSEI® across Australia.
Lightpoint has secured $8 Million in new finance from the British Business Bank and follow-on investor.
Dr Jochen Walz and his team at the Institut Paoli-Calmettes in Marseille are the first team in France to use SENSEI® with the da Vinci surgical robot.
First clinical use of SENSEI ® in robot-assisted cervical cancer surgery at UMC, Utrecht in the Netherlands using the da Vinci surgical robot.
David has more than a decade of experience in the medical imaging and pharmaceutical sectors. Previously, he was Head of Research Alliances at GE Healthcare and Head of Clinical Imaging at Novartis. Before joining industry, David served on the faculty of Harvard Medical School and Massachusetts General Hospital, Department of Radiology. He holds a PhD from MIT and Harvard Medical School, and a BA from the University of Chicago.
Claire is responsible for the day-to-day management of Lightpoint. She has more than ten years of experience in commercial operations, including six years in the medical device industry. Before joining Lightpoint she held board level positions in technology companies specializing in research and development. Claire is a CTA-qualified accountant. She holds an LLB with Honors in Law with Accounting and Finance from the University of Liverpool.
Simon heads up Lightpoint's finance team. He has 30 years’ experience in blue chip international organizations in the life science, healthcare, and leisure sectors. As an experienced finance leader, his diverse experience includes business strategy, business analytics, pricing, M&A activity, process improvement and streamlining, and financial management. Simon has a BA with Honors in Geography from the University of Exeter.
Stewart heads Lightpoint's in-house engineering team, which includes electronics, mechanical and software engineering. The team develops Lightpoint's products from concept to regulatory-approved medical devices. Stewart is an electronics engineer with over 20 years of experience in managing engineering teams.
Tony is responsible for Lightpoint's regulatory and quality teams, as well as operational project management. He has over 30 years of experience in product development, project management and quality systems. Tony has held senior positions with blue chip companies such as GE, Unilever, the BBC.
Klaas manages all of Lightpoint's multi-center clinical studies and supports clinicans running their own independent studies with our technologies. He has been managing clinical research for medical device companies for over two decades, including senior clinical positions at Stryker, Wright Medical and DePuy Synthes.
Kevin manages Lightpoint's global network of sales distributors, as well as adding commercial insight into new product development. He has over 20 years of experience in medical device business development, sales and world-wide distribution managment. Kevin has also, over many years, consulted with numerous early-stage life science companies to support product launches, determine regulatory and reimbursement strategies; and provide price analysis/positioning.
Jo is responsible for Lightpoint's external communication, as well as marketing and grant management. She has secured in excess of £8M in new non-dilutive funding for Lightpoint's R&D and clinical activities. Previous to Lightpoint she worked for over a decade in the not-for-profit sector, securing large-scale funding for charitable projects. Jo holds a BA with Honours in International History & Politics and an MPhil in Russian & East European Studies from Oxford University.
Kunal is responsible for Lightpoint's early-stage research before it transitions to the engineering team for formal product development. He is creating a pipeline of highly innovative technologies for intra-operative cancer detection across a wide range of major cancer indications. Kunal has almost a decade of experience in technical R&D in imaging and advanced sensors for medical devices. He holds a PhD in Experimental Physics from the University of Cambridge.
David has more than 20 years experience in the medical device industry. Formerly the Executive Director of BSI Group, he was responsible for the worldwide Healthcare and Testing activity for the British Standards Institution. David is currently CEO at Ingenica Solutions and a Non-Executive Director at NHS TrusTECH. David has represented the United Kingdom at the World Health Organization, the FDA and the European Commission in developing policy for medical devices and medical device regulation. David was trained at St. Mary’s Hospital Medical School, London and at Brunel University, and holds an MBA from INSEAD.
Nadim is the President and Chief Executive Officer of CVRx. He has previously served as Vice President and General Manager of Medtronic Navigation, the leading global supplier of integrated image-guided surgery products. He also worked at GE Medical for 10-years, where he was Vice President of Global Marketing for the OEC Medical Systems and Vice President and General Manager of GE’s European X-ray business based in Paris. Nadim has an engineering degree from Ecole Nationale Supérieure des Télécommunications, and an MBA from INSEAD, France.
Elizabeth has more than 20 years of experience in the medical device industry. She is currently the Executive Director & CEO of the American Academy of Dermatology (AAD), and was previously the Chief Marketing, Sales, and Communications Officer for the College of American Pathologists (CAP). Prior to joining CAP, she held executive leadership positions at GE Healthcare and Amersham Health. She has an MBA in International Business from Thunderbird School of Global Management and a Bachelor of Science degree from Georgia Institute of Technology.
After completing his early career in the pharmaceutical industry at Wyeth and 3M, Martin worked for Smiths Medical. Over 16 years he took on increasingly senior Managing Director roles, finally as Managing Director Smiths Medical International. Latterly, Martin has served as CEO of Rayner Surgical and CEO & Chairman of Nextism Plc, a medical device company focused on improving rehabilitation for stroke patients using non-invasive brain stimulation. Martin currently works with a number of private equity houses and is a Non-Executive Director of a large NHS Foundation Trust Hospital and multiple medtech SMEs.
At Lightpoint we're building a world-class team to transform the practice of cancer surgery. We hire trailblazing professionals who want to make a meaningful impact. We offer excellent benefits and perks. Come join us.
Lightpoint Medical, Ltd
HP5 1PE, United Kingdom
Phone: +44 (0)1494 917 697
Lightpoint Medical, Inc.
Regus Harvard Square
One Mifflin Place, Suite 400
Phone: +1 844 311 7083
Lightpoint Medical B.V.
Joop Geesinkweg 901-999
1114 AB, Netherlands
Phone: +31 20 561-6094
Lightpoint Medical Espana, S.L.
Rambla dels Països Catalans, s/n
Polígon Santa Magdalena
08800 Vilanova i la Geltrú, Barcelona, Spain
Phone: +34 935 951 649